Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Active, not recruiting · Phase 2 · NCT04879628
Conditions: Multiple Sclerosis
At a glance
- Research payments reported, 2025
- $55,816
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 129
About the trial
- Sponsor
- Sanofi
- Tested
- SAR441344 IV (drug), placebo IV (drug), SAR441344 SC (drug), placebo SC (drug), MRI contrast-enhancing preparations (drug)
- Dates
- Started 2021-06-07; completion 2027-08-23
- Results posted
- Yes
Primary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: * To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures * To evaluate the safety and tolerability of SAR441344 * To evaluate pharmacokinetics of SAR441344
From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $55,816 in research payments for this study in 2025 (20 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Neurological Instit,pa $51,726
- University of South Florida $4,090
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.